mTOR inhibition in T-cell lymphoma: A path(way) forward

Blood

Volumn 126, Issue 3, 2015, Pages 284-286

  Moskowitz, Alison J ^a   Horwitz, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELINOSTAT; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVEROLIMUS; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PRALATREXATE; PREDNISONE; RAPAMYCIN; ROMIDEPSIN; VINCRISTINE SULFATE; IMMUNOSUPPRESSIVE AGENT; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

CANCER SURVIVAL; HUMAN; NEGATIVE FEEDBACK; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T CELL LYMPHOMA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; FEMALE; LYMPHOMA, T-CELL; MALE; METABOLISM; NEOPLASM RECURRENCE, LOCAL;

ANIMALS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, T-CELL; MALE; MULTIPROTEIN COMPLEXES; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84937797977     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-644724     Document Type: Note

References (9)

1. Witzig TE, Reeder C, Han JJ, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126(3):328-335.
2. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182-1189.
3. Horwitz S, O'Connor O, Jurczak W, et al. Belinostat in relapsed or refractory peripheral T-cell lymphoma subtype angioimmunoblastic T-cell lymphoma: results from the pivotal BELIEF trial. Hematol Oncol. 2013;31(suppl 1):147.
4. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
5. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631-636.
6. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095-3100.
7. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9):729-734.
8. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res. 2010;16(20):4914-4920.
9. Horwitz SM, Porcu P, Flinn I, et al. Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma [abstract]. Blood. 2014;124(21). Abstract 803.